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Depression is a major public health concern with symptoms that are often poorly 
controlled by treatment with common antidepressants.  This problem is compounded in 
juveniles and adolescents, where therapeutic options are limited to selective serotonin 
reuptake inhibitors (SSRIs).  Moreover, therapeutic benefits of SSRIs are often 
especially limited in certain subpopulations of depressed patients, including children and 
carriers of low expressing serotonin transporter (SERT) gene variants.  Tricyclic 
antidepressants (TCAs) offer an alternative to SSRIs; however, how age and SERT 
expression influence antidepressant response to TCAs is not understood.  We 
investigated the relation between antidepressant-like response to the TCA desipramine 
using the tail suspension test and saturation binding of [3H]nisoxetine to the 
norepinephrine transporter (NET), the primary target of desipramine, in juvenile (21 
days post-natal [P21]), adolescent (P28) and adult (P90) wild-type (SERT+/+) mice.  To 
model carriers of low expressing SERT gene variants, we used mice with reduced 
SERT expression (SERT+/-) or lacking SERT (SERT-/-).  Maximal antidepressant-like 
effect and potency of desipramine were greater in P21 mice than in P90 mice, and were 
SERT genotype independent.  NET expression decreased with age in the locus 
coeruleus and increased with age in several terminal regions (e.g., CA1 and CA3 
regions of hippocampus).  Binding affinity of [3H]nisoxetine did not vary as a function of 
age or SERT genotype. These data show age-dependent shifts for desipramine to 
produce antidepressant-like effects that correlate with NET expression in the locus 
coeruleus and suggest that drugs with NET blocking activity may be an effective 
alternative to SSRIs in juveniles. 






Depression is a major public health concern with symptoms often poorly 
controlled with commonly prescribed antidepressants.  This problem is compounded in 
juveniles and adolescents by fewer pharmacological treatment options compared to 
adults (Bylund and Reed, 2007).  The Food and Drug Administration (FDA) has 
approved two antidepressant drugs, fluoxetine and escitalopram, for use in treating 
pediatric depression.  Both drugs are selective serotonin (5-HT) reuptake inhibitors 
(SSRIs), which prevent 5-HT uptake via the 5-HT transporter (SERT).  SSRIs can be 
effective treatments for adult patients suffering from depression, but often fail to relieve 
all depressive symptoms (Kirsch et al., 2008).  The therapeutic benefit of SSRIs can be 
especially limited in children and in carriers of a common SERT gene variant that yields 
lower SERT expression (Kessler et al., 2001; Serretti et al., 2007; Bujoreanu et al., 
2011).  Tricyclic antidepressants (TCAs) are an alternative to SSRIs.  However, in 
juveniles and adolescents, TCAs are not FDA approved for the treatment of depression, 
and are prescribed infrequently due to serious side effects.  Amitriptyline poisoning, a 
condition more dangerous in children than in adults, is one example (Paksu et al., 
2014).  Given that studies on the therapeutic benefit experienced by juveniles and 
adolescents and by carriers of low expressing SERT gene variants from TCA treatment 
have reported mixed results (Hazell et al., 1995; Rajewska-Rager et al., 2008; Perlis et 
al., 2010; Hazell and Mirzaie, 2013), there is a need to better understand the age- and 
SERT gene variant-dependency of TCA efficacy as a first step towards developing 
improved antidepressants for these populations.     




TCAs primarily act to block the norepinephrine transporter (NET), but some also 
block SERT.  The ensuing increase in extracellular norepinephrine (NE) and 5-HT is 
thought to trigger therapeutic downstream events (Frazer, 1997).  It has been 
suggested that a developmental delay in the noradrenergic central nervous system may 
limit the antidepressant potential of NET targeting TCAs in juveniles and adolescents 
compared with adults (Bylund and Reed, 2007).  However, other reports go against this 
idea.  For example, in rats, innervation of noradrenergic neurons into higher brain 
regions, such as the cortex, reach adult-like morphology by postnatal day (P) 7 (Loizou, 
1972; Lauder and Bloom, 1974; Coyle, 1977; Thomas et al., 1995).  Noradrenergic 
receptors reach adult levels by P14 – P21, and norepinephrine content reaches adult 
levels by P14 – P42 (Loizou and Salt, 1970; Konkol et al., 1978; Morris et al., 1980; for 
review see Murrin et al., 2007).  In juvenile and adolescent rats, NET expression is 
reported to be greater or equivalent to that in adults in numerous brain regions (Moll et 
al., 2000; Sanders et al., 2005).  These findings suggest that NET selective TCAs, such 
as desipramine (DMI), should produce antidepressant-like effects in juvenile (P21) and 
adolescent (P28) rodents, because the noradrenergic system is relatively established at 
these ages.   
However, there is a paucity of research investigating antidepressant-like effects 
of TCAs in juvenile and adolescent rodents.  In rats, the TCAs imipramine and DMI 
have been reported to be less effective in producing antidepressant-like effects in the 
forced swim test (FST) in juveniles than in adults.  In contrast, we found that 32 mg/kg 
DMI produced equivalent antidepressant-like effects in mice aged P21, P28 and P64-90 
(young adult) in the tail suspension test (TST) (Mitchell et al., 2013).    These behavioral 




results were paralleled by [3H]nisoxetine binding in whole hippocampal homogenates, 
which revealed no difference in NET expression among these ages.  While informative, 
these studies provided no information on how age may affect the potency or maximal 
effect of DMI to produce antidepressant-like effects in the TST.  [3H]Nisoxetine binding 
assays in hippocampal homogenates also lack the ability to discriminate potential 
differences in NET expression among hippocampal sub-regions as a function of age, 
and do not provide information about other brain regions that may be important in 
mediating antidepressant-like effects.  
Determination of the potency and maximal effect of DMI to produce 
antidepressant-like effects in the TST, as well as establishing the ontogeny of NET 
expression throughout early postnatal development could help to identify age-
dependent mechanisms that may limit the therapeutic benefit of antidepressants.  Here, 
we examined the dose-response relationship for DMI to produce antidepressant-like 
effects in P21, P28 and P90 SERT-deficient mice, and quantified NET expression in a 
number of brain regions using autoradiography with [3H]nisoxetine, a NET-selective 
ligand.  SERT-deficient mice were included in this study to assess effects of constitutive 
reduction in SERT expression, which occurs in humans carrying low expressing gene 
variants of SERT, on antidepressant-like effects of DMI, and on NET expression and 
affinity.    
  




MATERIALS AND METHODS 
Animals 
Naïve male and female SERT wild-type (SERT+/+), heterozygote (SERT+/-) or 
homozygote knockout (SERT-/-) mice (backcrossed to C57BL/6J for >10 generations) 
were used for all experiments.  Dr. Dennis Murphy (National Institute of Mental Health) 
provided mice to found the colony.  Animals were bred by crossing male and female 
SERT+/- mice, and SERT-genotypes were identified as previously described (Bengel et 
al., 1998). Mice were aged P21 (juvenile), P28 (adolescent), and P90-P100 (adult) 
(Spear, 2000) for all experiments.  Animals were housed in a temperature-controlled 
(24°C) vivarium maintained on a 12/12-hr light/dark cycle (lights on at 7:00 am) in 
plastic cages (29 cm x 18 cm x 13 cm) containing rodent bedding (Sani-chips, Harlan 
Teklad, Madison, WI, USA) with free access to food (irradiated rodent sterilizable diet, 
Harlan Teklad, Madison, WI, USA) and water.  Weaning occurred at P28, after which 
mice were housed with five of their same-sex peers. To avoid possible confounds of 
treatment effects with litter effects, no more than one mouse from a given litter was 
assigned to a particular treatment condition. All procedures were conducted in 
accordance with the National Institute of Health Guide for the Care and Use of 
Laboratory Animals (Institute of Laboratory Animal Resources, Commission on Life 
Sciences, National Research Council, https://grants.nih.gov/grants/olaw/Guide-for-the-
Care-and-use-of-laboratory-animals.pdf), and with the approval of the Institutional 
Animal Care and Use Committee, The University of Texas Health Science Center at 
San Antonio. 
Tail suspension test 




TST experiments were conducted as originally described by Steru et al. (1985) 
with minor modifications (described in Mitchell et al., 2015).  In brief, mice were moved 
from a housing facility to a testing room then given a 1-2 h acclimation period prior to 
TST.  Experiments were conducted in the afternoon, between 12:00 noon and 5:00 pm.  
Mice received an intraperitoneal (i.p.) injection of saline 1 h prior to test, followed by an 
i.p. injection of either DMI (3.2, 10 or 32 mg/kg) or saline vehicle (control condition) 30 
min prior to test.  This two injection protocol was used to be consistent with previous 
studies from this laboratory (Baganz et al., 2008; Horton et al., 2013) and with future 
studies that will examine the effects of drug combinations on immobility time in the TST.  
Immediately before testing, the distal portion of the tail was secured to a flat aluminum 
(2 X 0.3 X 10 cm) bar using adhesive tape.  A hole on the opposite end of the bar was 
secured to a hook in a visually isolated white box (40 X 40 X 40 cm).  Each mouse was 
suspended for 6 min while a digital video camera recorded its ventral surface.  
Immobility was defined as the absence of active movements, and included passive 
swaying.  Immobility time was scored in s by observers blind to the randomly assigned 
treatment conditions.  Mice were tested only once.   
Drugs 
Desipramine (desmethylimipramine) hydrochloride [Sigma-Aldrich (St. Louis, 
MO, USA)] was dissolved in physiological saline and injected i.p. at doses expressed as 
salt weight per kilogram body weight.  The injection volume was 10 ml/kg.  
Autoradiography 




NET density in mouse brain was assessed by quantitative autoradiography using 
the NET-selective ligand [3H]nisoxetine and methods adapted from Tejani-Butt (1991).  
Mice were killed by decapitation and brains were flash frozen on powdered dry ice 
before being stored at -80 °C.  Before sectioning, brains were brought to -20 °C in a 
cryostat (Leica CM 1850, Meyer Instruments, Houston, TX).  Coronal sections (20 µm) 
were collected at the level of plate 12 (prefrontal cortex), plate 47 (hippocampal sub-
regions [Cornu Ammonis (CA) 1, 2, 3 and dentate gyrus], amygdala, plate 64 (raphe 
nuclei), and plate 76 (locus coeruleus) according to Paxinos and Franklin’s mouse brain 
atlas (1997).  Sections were thaw mounted onto gelatin-coated microscope slides.  
Tissue mounted slides were vacuum desiccated for 18-24 h at 4 °C before storing slides 
at -80 °C.  Brain tissue was stored at -80 °C for 2 – 4 weeks, and every experiment 
contained brain tissue from all groups, including P21, P28 and P90 SERT+/+, SERT+/- 
and SERT-/- male and female mice.  Before incubation, sections on slides were thawed 
for 1 h in a vacuum desiccator at 4°C to remove excess moisture and maximize brain 
tissue adherence to slides.  The slides were then pre-incubated for 1 h in a 43 mM Tris-
HCl, 124 mM NaCl, and 4.3 mM KCl pH 7.4 wash buffer solution at room temperature (~ 
24°C) to remove endogenous ligands bound to NET.  Incubation was carried out in slide 
mailers (VWR, USA) filled with 10 ml of 50 mM Tris-HCl, 300 mM NaCl, and 5 mM KCl 
pH 7.4 ice cold reaction buffer containing [3H]nisoxetine at concentrations of 0.3, 1.0, 
3.0, 10, or 3.0 nM for 4 h.  Each concentration of [3H]nisoxetine was incubated with 3 
brain sections per animal per brain region.  Non-specific binding was defined by 2.5 mM 
mazindol (Pfizer, Groton CT) and was ~9-50 % total binding in low binding regions (i.e. 
CA1) and ~9-22 % total binding in high binding regions (i.e. locus coeruleus).  The 




incubation was terminated by three 5 min washes in wash buffer solution at 4 °C, 
followed by a 5 s dip in de-ionized water at 4 °C.  Slides were dried on a slide warmer 
for 20 min.  [3H]Nisoxetine labeled sections were exposed to Carestream Biomax MR 
film for 6 weeks, along with tritium standards (American Radiolabeled Chemicals, St 
Louis, MO).  Films were developed in a film processor (AFP imaging, Elmsford, NY).  A 
digital imaging system that included a 12-digital bit camera (CFW-1612M, Scion Corp., 
Frederick, MD), Nikon Lens, Northern Lights Illuminator and Kaiser RS1 copy stand (all 
from InterFocus Imaging Ltd., Linton, England) was used to capture autoradiogram 
image.  Autoradiograms were calibrated and measured using NIH Image J public 
access shareware (https://imagej.nih.gov/ij/download.html) on a MacBook (OS 10).  
Additional brain sections we stained with thionine (FD NeuroTechologies, INC, 
Columbia, MD, USA) to verify tissue integrity and neuroanatomical brain regions 
quantified (Figure 2.B and 3.B).   
Data analysis 
Statistical analyses were performed using Prism 6.0 (GraphPad, San Diego, CA, 
USA) and NCSS 2007 (Kaysville, UT, USA).  
TST:  
Dose response curves were generated by administering 3.2, 10, or 32 mg/kg 
DMI or saline vehicle in juvenile, adolescent or adult mice.  Under vehicle conditions, we 
previously found that time spent immobile varies by age and SERT-genotype (Mitchell 
et. al., 2013; 2015; 2016).  Because such differences were also apparent in the present 
study, (see vehicle data in Figure 1.A-C), we have expressed data as total immobility in 




(s) (Figure 1.A-C), then replotted these data as percent from saline vehicle control 
(Figure 1.D-F).  Within genotype, TST data were analyzed by two-factor ANOVA (age, 
drug dose) followed by Dunnett’s and Tukey’s multiple comparisons tests.  Sample 
sizes for TST data included 9 - 14 SERT+/+ males and 10 - 20 SERT+/+ females, 8 - 10 
SERT+/- males and 16 - 20 SERT+/- females, and 8 - 10 SERT -/- males and 9 - 14 
SERT-/- females, per data point.  A multifactor ANOVA showed neither a main effect of 
sex nor any interaction of sex with other factors (P = 0.51 and P ≥ 0.10, respectively), 
with the exception of a sex x genotype interaction (P = 0.008); however, multiple 
comparisons failed to show significant sex differences for each of the genotypes.  Thus, 
data for males and females were combined.  Maximal effects (Emax) and half-
maximally effective dose (ED50) were derived from data in Figure 1.D-F and are 
summarized in Table 1.  Emax was defined as the greatest observed percent change of 
immobility from saline control.  Emax values were analyzed by two-factor ANOVA (age, 
SERT genotype) followed by Tukey’s multiple comparisons test (Table 1).  ED50 values 
were calculated using methods detailed in Koek et al. (2009).  Briefly, the linear portion 
of the dose-response curves was analyzed by log-linear regression (effect = slope X 
log(dose) + intercept) of data from individual subjects.  All data are expressed as mean 
± standard error of the mean (SEM), except ED50 values, which are expressed as the 
mean.  P < 0.05 was considered statistically significant.   
Quantitative Autoradiography: 
[3H]Nisoxetine binding densities were measured from autoradiograms and 
analyzed using methods described in Mitchell et al., (2016).  In brief, non-specific 
binding was fit to an unweighted linear regression and subtracted from total 




[3H]nisoxetine to give specific binding.  Unweighted non-linear regression was used to 
analyze [3H]nisoxetine specific binding data. Saturation binding isotherms were fitted 
according to a one site model: Y = Bmax * X / (Kd + X) to calculate maximal specific 
[3H]nisoxetine binding (Bmax) and affinity (Kd) values (Figure 2 and 3).  Bmax and Kd 
values were analyzed with a two-factor (age, genotype) ANOVA (Figure 4 and Table 2).  
Within genotype- and brain region-matched groups there were no statistically-significant 
effects of sex (P ≥ 0.09) or sex and age interactions (P ≥ 0.17) for [3H]nisoxetine Bmax 
or Kd values; thus, data from both sexes were combined.  Two-factor ANOVA (age, 
SERT genotype) (Figure 4) followed by Dunnett’s post hoc test for multiple comparisons 
was used to analyze mean Bmax and Kd values.  All data are expressed as mean ± 
standard error of the mean (SEM). P < 0.05 was considered statistically significant.   
Correlations:   
As shown in Figure 5.A-E, Pearson’s correlation was used to examine the 
relation between Emax for DMI to reduce immobility time in the TST and maximal 
specific [3H]nisoxetine binding, as a function of age.  Within each brain region, SERT 
genotype did not significantly influence the relation between Emax for DMI and maximal 
specific [3H]nisoxetine binding (P ≥ 0.15; data not shown) so data for SERT+/+, 
SERT+/- and SERT-/- were best fit with a single line (Figures 5.A-E).  All data are 
expressed as mean ± standard error of the mean (SEM). 
  





The potency of desipramine to reduce immobility time in the tail suspension test 
depends on age and SERT genotype, while its maximal effect depends on age 
only.  
Clinical studies have shown that therapeutic potential of SSRIs is limited in 
children (Kirsch et al., 2008).  Similar, we have previously found the antidepressant-like 
response to SSRIs in juvenile mice is limited in comparison to adult mice (Mitchell et al., 
2013; Mitchell et al., 2016).  As an alternative to SSRIs, we began our study by 
evaluating the antidepressant-like response to DMI, a potent NET blocker, in SERT+/+ 
P21, P28 and P90 mice.  Using the TST, we found that DMI reduced immobility time in 
all age groups [F(3,276) = 35.06, P < 0.01], and younger mice spent overall less time 
immobile than adult mice [F(2,276) = 19.73, P < 0.01] (Figure 1.A).  An interaction 
between age and DMI dose showed that younger mice are more sensitive to the anti-
immobility effects of DMI than adults [F(6,276) = 2.34, P = 0.03].  Post hoc analysis 
revealed that immobility time was significantly lower in P21 mice than in P28 and P90 
mice after administration of 10 mg/kg DMI (P < 0.01), and immobility time was lower in 
P21 mice than in P90 mice after administration of 3.2 and 32 mg/kg DMI (P < 0.01, P = 
0.012).  Likewise, immobility time at 3.2 mg/kg DMI was significantly lower in P28 mice 
than in P90 mice (P < 0.01).  3.2 mg/kg DMI was the lowest effective dose in P21 and 
P28 mice, and 10 mg/kg was the lowest effective dose in P90 mice (P < 0.01).  Taken 
together, the anti-immobility effects of DMI appear to be greater in younger mice than 
adults.  




Clinical studies have also found that the antidepressant effects of SSRIs are 
limited in individuals with a SERT gene polymorphism that yields a reduction in SERT 
expression/function (Serretti et al., 2007).  We utilized SERT+/- mice, which express 50 
percent less SERT than SERT+/+ mice, to evaluate the antidepressant-like potential of 
NET blockade in individuals with reduced SERT expression/function.  DMI reduced 
immobility time in the TST [F(3,212) = 16.58, P < 0.01] (Figure 1.B), and younger mice 
spent overall less time immobile in the TST than adult mice [F(2,212) = 9.34, P < 0.01].  
In contrast with SERT+/+ mice, no interaction was found between age and DMI drug 
dose in SERT+/- mice [F(6,212) = 0.81, P = 0.57].  Post hoc analysis showed that 
immobility time in the TST was lower in vehicle-treated P28 mice than vehicle-treated 
P90 mice (P < 0.01).  The lowest effective dose for P21 and P90 mice was 3.2 mg/kg 
DMI (P < 0.01).  While no dose of DMI significantly reduced immobility time in P28 mice, 
immobility times following 32 mg/kg DMI trended to be lower than immobility times 
following vehicle treatment (P = 0.087).  These data suggest antidepressant-like effects 
of DMI are not greater in younger SERT+/- mice than in adult mice; however, variation 
in basal immobility (saline vehicle control) as seen with P28 SERT+/- mice may limit the 
interpretation of our findings. 
While DMI is a potent NET blocker, it does have affinity for SERT.  The 
antidepressant-like effect of DMI in SERT-/- mice was evaluated to investigate the 
proportion of antidepressant-like response that was SERT-dependent in P21, P28 and 
P90 mice.  Immobility time in the TST was reduced after DMI administration [F(3,217) = 
9.00, P < 0.01], although no dose of DMI significantly lowered immobility time in P28 
mice (P = 0.13).  A main effect of age was also found [F(2,217) = 6.14, P < 0.01] (Figure 




1.C).  No interaction between age and drug dose was found [F(6,217) = 0.29, P = 0.94].  
Immobility time was lower in P21 and P90 mice than in P28 mice after administration of 
10 mg/kg DMI (P = 0.015, P < 0.01).  The lowest effective dose for P21 and P90 mice 
was 10 mg/kg DMI (P < 0.01; P = 0.04).  These data suggest that NET blockade is 
primarily responsible for the antidepressant-like effects of DMI in the TST, with the 
possible exception of P28 SERT-/- mice where, as for SERT+/- mice, no dose of DMI 
significantly reduced immobility time (Figure 1.C).  
It should be noted that basal immobility time in the TST was lower in SERT-/- 
mice (Figure 1.C) compared to SERT+/+ mice (Figure 1.A), and P28 SERT+/- mice 
showed less basal immobility in comparison to P90 SERT+/- mice (Figure 1.B).  To 
account for age and SERT genotype related variations in basal immobility time, data 
were normalized to a percent of vehicle control (Figure 1.D-F).  Analysis of normalized 
SERT+/+ data was similar to the analysis of raw SERT+/+ data (in s) with minor 
exceptions.  DMI reduced immobility time in all SERT+/+ age groups [F(3,276) = 36.23, 
P < 0.01], and a main effect of mouse age was found [F(2,276) = 10.36, P < 0.01] 
(Figure 1.D).  Younger mice showed greater sensitivity to the anti-immobility effects of 
DMI in the TST than adult mice [F(6,276) = 2.58, P = 0.02].  Immobility time was 
significantly lower in P21 SERT+/+ mice than in P90 mice following 3.2 mg/kg (P < 0.01) 
and 10 mg/kg DMI (P = 0.04).  Immobility time was lower in SERT+/+ P28 mice than in 
P90 mice following 3.2 mg/kg DMI (P < 0.01).  The lowest effective dose for DMI was 
3.2 mg/kg in SERT+/+ mice aged P21 and P28 (P < 0.01), and the lowest effective dose 
for P90 mice was 10 mg/kg (P < 0.01). 




Analysis of normalized SERT+/- data showed that DMI reduced immobility time in 
the TST [F(3,212) = 15.7, P < 0.01], with no main effect of age [F(2,212) = 2.091, P = 
0.13] (Figure 1.E).  DMI reduced immobility time in all age groups, and did so equally 
across all age groups [F(6,212) = 0.46, P = 0.84].  No differences among age groups 
were found.  The lowest effective dose for P21 and P90 SERT+/- mice was 3.2 mg/kg 
DMI (P < 0.01; P = 0.03, respectively).  The lowest effective dose for P28 SERT+/- mice 
was 32 mg/kg DMI (P = 0.02).  By normalizing SERT+/- data, we found that DMI 
reduced immobility in all age groups, including P28 SERT+/- mice. 
Normalized data for SERT-/- mice showed a main effect of DMI [F(3,217) = 9.01, 
P < 0.01] and age [F(2,217) = 4.20, P = 0.02] (Figure 1.F).  Like SERT+/- mice, there 
was no interaction between age and drug dose [F(6,217) = 0.27, P = 0.95].  After 10 
mg/kg DMI, immobility time was significantly lower in P21 and P90 SERT-/- mice than in 
P28 mice (P = 0.02; P = 0.03).  The lowest effective dose for P21 and P90 SERT-/- 
mice was 10 mg/kg (P = 0.02), and no dose significantly reduced immobility time in P28 
mice including 32 mg/kg DMI (P = 0.17).   
To investigate a possible interaction between postnatal age and SERT genotype 
on the antidepressant-like response to DMI, we compared the potency (ED50) and 
maximal effect (Emax) of DMI at different ages and in different genotypes (Table 1).  
With the exception of P28 SERT+/- and SERT-/- mice, ED50 values for DMI were lower 
in younger mice than in adults.   ED50 values for DMI varied as a function of age in 
SERT+/+, SERT+/- and SERT-/- mice [F(2,205) = 12.57, P < 0.01; F(2,163) = 3.22, P 
=0.04; F(2,149) = 3.38, P = 0.04; respectively].  In SERT+/+ mice, the ED50 value was 
lower in P21 mice than in P28 mice and P90 mice [F(1,125) = 6.75, P = 0.02; F(1,143) = 




25.0, P < 0.01], and P28 mice had a lower ED50 value than P90 mice [F(1,143) = 5.2, P 
= 0.02].  In SERT+/- mice ED50 values were lower in P21 mice than in P28 mice 
[F(1,105) = 5.7, P = 0.02]. In SERT-/- mice ED50 values were lower in P21 mice than in 
P28 mice [F(1,96) = 9.33, P < 0.01].  Among SERT genotype comparisons showed an 
effect of SERT genotype in P28 mice [F(2,167) = 5.50, P < 0.01].  P28 SERT+/+ mice 
showed a lower ED50 than P28 SERT-/- mice [F(1,116) = 12.25, P < 0.01].  SERT-
genotype had no significant main effect on ED50 values in P21 or P90 mice [F(2,177) = 
1.29, P = 0.28; F(2,193) = 0.82, P = 0.44].  In P28 mice, an effect of SERT genotype 
was found [F(2,167) = 5.50, P < 0.01].  P28 SERT+/+ mice had a lower ED50 value than 
P28 SERT-/- mice [F(1,116) = 12.25, P < 0.01]. 
The Emax for DMI to reduce immobility time in the TST was significantly greater 
in young mice than in adults [F(2,178) = 7.06, P < 0.01].  P21 SERT+/+ mice showed a 
significantly greater Emax than P90 SERT+/+ mice (P = 0.046).  As well, the Emax for 
DMI in P21 SERT-/- mice was greater than P28 SERT-/- mice (P = 0.02).  SERT 
genotype did not affect the Emax for DMI to reduce immobility time [(2,178) = 1.043, P = 
0.35], and SERT genotype did not interact with the effects of age. [F(4,178) = 0.94, P = 
0.44].   
Collectively, the ED50 values for DMI to decrease immobility time in the TST were 
lowest in P21 mice, regardless of SERT genotype.  Emax values for DMI were greater 
in P21 mice than in P28 and P90 mice.  The role of SERT genotype in antidepressant-
like response to DMI was most apparent in P28 mice, where drug potency decreased 
with the reduction and loss of SERT, although a similar trend was observed with P21 
mice as well (Table 1). 




NET expression increased with age in some noradrenergic terminal regions and 
decreased with age in the locus coeruleus.  
In an effort to explain the age-dependent antidepressant-like response to DMI, 
NET binding densities were quantified in limbic (CA1, CA2, CA3, dentate gyrus, 
prefrontal cortex and amygdala) and cell body (dorsal raphe and locus coeruleus) 
regions using quantitative autoradiography to measure specific [3H]nisoxetine binding.  
Figures 2.A and 3.A show representative autoradiograms.  Figures 2.B and 3.B are 
thionine stained tissue sections to confirm tissue integrity and to highlight brain regions 
quantified where significant differences were found.  These sections are a 
representative enlargement of the boxed areas shown in the top right panels of Figures 
2.A and 3.A.  Figures 2.C and 3.C show summary data for specific binding in SERT+/+ 
mice in the CA3 region of hippocampus and locus coeruleus, respectively.  Bmax and 
Kd values were analyzed with a two-factor (age, genotype) ANOVA (Figure 4 and Table 
2) to determine how age and SERT-genotype influence NET binding densities in brain 
regions of potential importance for TCAs antidepressant-like response.  These results 
are described below.   
[3H]Nisoxetine Bmax and Kd values in terminal regions: 
 In the hippocampus, specific [3H]nisoxetine Bmax values significantly increased 
with age in the CA1 and CA3 [F(2,52) = 4.53, P = 0.02; F(2,52) = 5.40, P < 0.01], but 
not in the CA2 region of hippocampus or dentate gyrus [F(2,52) = 2.71, P = 0.08; 
F(2,52) = 0.42, P = 0.66] (Figure 4.A-D).  Bmax values in P90 SERT+/+ mice were 
greater than in P21 SERT+/+ mice in CA1 and CA3 (P = 0.02; P < 0.01) (Figure 4.A,C,).  
Bmax values did not vary as a function of SERT genotype in the CA1, CA2, CA3 




regions of hippocampus or dentate gyrus [F(4,52) = 1.60, P = 0.19; F(2,52) = 0.21, P = 
0.80; F(2,52) = 0.78, P = 0.46; F(2,52) = 0.87, P = 0.42, respectively].  Additionally, no 
interactions between age and SERT genotype on Bmax values were found in these 
regions [F(2,52) = 1.76, P = 0.18; F(4,52) = 0.57, P = 0.69; F(4,52) = 0.68, P = 0.61; 
F(2,52) = 0.42, P = 0.66, respectively]. 
While not statistically significant, Bmax values tended to increase with age in the 
prefrontal cortex and amygdala [F(2,52) = 3.04, P = 0.056; F(2,52) = 2.32, P = 0.11] 
(Table 2).  Among age comparisons showed greater Bmax values for P90 SERT+/+ 
mice than P21 SERT+/+ mice in the prefrontal cortex (P = 0.05), and Bmax values were 
greater in P90 SERT+/+ mice than P28 SERT+/+ mice in the amygdala (P < 0.01).  As 
for hippocampus, Bmax values in the prefrontal cortex and amygdala did not vary as a 
function of SERT genotype [F(2,52) = 1.30, P = 0.28; F(2,52) = 1.81, P = 0.18, 
respectively].  No interaction between age and SERT genotype on Bmax values was 
found in these regions [frontal cortex: F(4,52) = 0.79, P = 0.54; amygdala: F(4,52) = 
1.30, P = 0.28].  Within the dorsal raphe, Bmax values were not dependent on either 
age or SERT genotype [F(2,52) = 0.78, P = 0.46; F(2,52) = 0.36, P = 0.70] (Table 2).  
No interaction between age and SERT genotype on Bmax values was found [F(4,52) = 
0.58, P = 0.68].   
Kd values in all terminal regions ranged from 1.0 – 5.5 nM and were not 
dependent on age (P ≥ 0.44) or SERT genotype (P ≥ 0.5).  
[3H]Nisoxetine Bmax and Kd values in cell body regions: 




Specific [3H]nisoxetine Bmax values decreased with age in the locus coeruleus 
[F(2,52) = 5.11, P < 0.05] (Figure 4.E):  Bmax values were greater in P21 SERT-/- mice 
than in P90 SERT-/- mice (P = 0.03).  Bmax values did not appear to depend on SERT 
genotype [F(2,52) = 2.53, P = 0.09] and no interaction between age and SERT 
genotype was found [F(4,52) = 1.00, P = 0.41]. 
In the locus coeruleus Kd values ranged from 0.52 – 0.75 nM and did not depend 
on age (P = 0.67) or SERT genotype (P = 0.25). 
Relationship between maximal antidepressant-like effects of DMI in the tail 
suspension test and maximal binding values for [3H]nisoxetine in hippocampus 
and locus coeruleus. 
Terminal regions: 
Figure 5. A-D shows a negative relation between Emax values for DMI’s anti-
immobility effects in the TST and Bmax values for specific [3H]nisoxetine binding in 
CA1, CA2 and CA3 regions and dentate gyrus of hippocampus of P21, P28 and P90, 
SERT+/+, SERT+/- and SERT-/- mice.  In all regions, the relation between Emax and 
Bmax was not significantly influenced by SERT genotype (P ≥ 0.15); thus, the data were 
pooled across genotype and were fitted with a single line (Pearson’s correlation: r = -
0.66, r = -0.74, r = -0.65, r = -0.26; for CA1, CA2, CA3 and dentate gyrus). 
Cell body regions: 
Figure 5.E shows a positive relation between Emax values for DMI’s anti-
immobility effects in the TST and Bmax values for specific [3H]nisoxetine binding in 
locus coeruleus.  As for hippocampus, the relation between Emax and Bmax in the 




locus coeruleus was not affected by SERT genotype (P = 0.88); data from SERT+/+, 
SERT+/- and SERT-/- mice were therefore pooled and fitted with a single line 
(Pearson’s correlation: r = 0.41).   





Here, we found the potency and Emax of DMI to be greater in juvenile (P21) and 
adolescent (P28) SERT+/+ mice than in adult (P90) SERT+/+ mice (Table 1).  
Regardless of SERT genotype, NET expression, quantified by specific [3H]nisoxetine 
binding using autoradiography, increased with age in hippocampus (Figure 4.A-D), and 
decreased with age in locus coeruleus (Figure 4.E).  Age-related changes in Emax for 
DMI to reduce immobility were negatively related with Bmax values for specific 
[3H]nisoxetine binding in hippocampus and positively related with Bmax values in locus 
coeruleus (Figure 5.A-E).  Thus, there is an inverse relation between maximal 
antidepressant-like response following DMI and NET expression in hippocampus, where 
antidepressant-like response to DMI decreases with age and NET expression 
increases.  In contrast, NET expression in the locus coeruleus and antidepressant-like 
response to DMI decreases with increasing age.  These data reveal a complex 
relationship between antidepressant-like response to DMI and NET expression, 
suggesting that the antidepressant-like effect of DMI may be reliant on brain regions 
such as the locus coeruleus.   
The TCA imipramine, a NET and SERT blocker, is known to reduce immobility 
time of adolescent mice (P28 and P35) in the FST, an assay of antidepressant-like 
response (Bourin et al., 1998; David et al., 2001; Mason et al., 2009).  Adolescent (P28 
and P35) mice also respond to the anti-immobility effects of imipramine and DMI in the 
TST (Mason et al., 2009; Mitchell et al., 2013), and DMI reduces immobility time in the 
FST in adolescent (P28 and P30) rats (Pechnick et al., 2008; Reed et al., 2008).  Our 
SERT+/+ mouse data agree with literature showing that adolescents (P28) are sensitive 




to the antidepressant-like effects of DMI (Mitchell et al., 2013).  We found that juvenile 
(P21) SERT+/+ mice are more sensitive to the antidepressant-like effects of DMI in the 
TST than P28 mice. These data deviate from experiments using juvenile (P21) rats 
showing that DMI does not significantly reduce FST immobility (Reed et al., 2008).  
Possible reasons for this discrepancy are a difference in species (mice vs rats), in 
behavioral assay (TST vs FST) and in injection schedule.  The FST and TST differ in 
their sensitivity to detect antidepressant-like activity, which can vary with rodent strain, 
thus discrepancies such as this are expected (Cryan et al., 2005).   
The SERT-deficient mouse provides a model of SERT gene variants that confer 
a reduction in SERT expression and/or function and a reduction in SSRI efficacy (Fox et 
al., 2007; Serretti et al., 2007; Homberg and Lesch, 2011).  Our findings are consistent 
with reports that DMI and imipramine reduce immobility in adult SERT+/+, SERT+/- and 
SERT-/- mice in the TST (Figure 1; Holmes et al., 2002).  Studies investigating 
treatment outcomes of patients with low expressing SERT gene variants treated with 
TCAs are limited.  Reports using duloxetine, a SERT and NET blocker, and nortriptyline, 
a NET selective blocker, have failed to show any association with treatment outcome 
and low expressing SERT gene variants (Rajewska-Rager et al., 2008; Perlis et al., 
2010).  Our results from P28 SERT+/- mice suggest that DMI may have especially 
limited therapeutic efficacy in adolescents harboring low expressing SERT gene 
variants, although the exact mechanism for this remains unknown. 
ED50 values increased with age from P21, confirming a similar effect of age in 
adult (P90) to middle-aged (P300) mice (Table 1; Mitchell et al., 2015). Like DMI 
potency, Emax values were greatest in SERT+/+ P21 and P28 mice compared with 




adults (Table 1).  These findings are consistent with a study showing a greater 
antidepressant-like Emax of imipramine in adolescent mice (P28) than in adults using 
the FST (David et al., 2001).  Emax values were not dependent on SERT genotype, 
which is consistent with studies showing no difference in Emax values between P90 
SERT+/+ and P90 SERT+/- or P90 SERT-/- mice (Mitchell et al., 2015).   
It should be noted that we cannot rule out other age-dependent factors as 
modulators of antidepressant-like response, i.e., expression and function of 
noradrenergic receptors, pharmacokinetic parameters, and expression of NE 
synthesizing enzymes (Murrin et al., 2007).  Future studies are needed to better 
understand the ontogeny of the noradrenergic system and how changes in these 
parameters may influence the response to psychoactive therapeutics. 
The therapeutic benefit of a drug may be impacted by its tolerability.  Pediatric 
patients treated with TCAs consistently showed side effects such as vertigo, tremors, 
low blood pressure and dry mouth (Hazell and Mirzaie, 2013).  Side effects do not 
necessarily limit antidepressant-like drug effects in the TST. Thus, our findings suggest 
TCAs may be efficacious antidepressants in juveniles (lower ED50 and greater Emax), 
but low tolerability of TCAs may limit the therapeutic benefit of TCAs in pediatric 
patients.  Therefore, our results encourage further investigation of the utility of NET, 
and/or dual NET and SERT blockers in the treatment of pediatric depression and the 
development of new drugs that target transporters for NE and 5-HT but have fewer side 
effects.   
To elucidate the mechanism underlying age-related changes in the 
antidepressant-like response to DMI we used quantitative autoradiography to assess 




[3H]nisoxetine binding to NET (Figure 2 and 3).  Specific [3H]nisoxetine binding densities 
generally increased with age in noradrenergic terminal regions.  Bmax values were 
greater in adult CA1 and CA3 hippocampal regions than in younger mice (Figure 4.A,C).  
Bmax values trended to increase with age in the CA2, dentate gyrus, prefrontal cortex 
and amygdala (Figure 4.B,D and Table 1).  These findings partially diverge from 
experiments using [3H]nisoxetine saturation binding with whole hippocampus mouse 
homogenate, where no age related differences in Bmax values among P21, P28 and 
P90 mice were found (Mitchell et al., 2013).  It is conceivable that hippocampal sub-
region differences in NET expression, which can be revealed by quantitative 
autoradiography, limited the ability to detect age related changes in Bmax values for 
[3H]nisoxetine binding when using hippocampal homogenate preparations.  Notably, the 
Kd values for [
3H]nisoxetine here (0.5 – 5.5 nM) are consistent with Kd values from 
hippocampal homogenate preparations (2.5 – 7.4 nM) (Mitchell et al., 2013).  
In rat hippocampus, triphasic [3H]nisoxetine binding patterns from birth through 
adulthood have been observed (Sanders et al., 2005).  Binding densities increased 
postnatally, peaked between P15 – P25 and decreased into adulthood.  In contrast, we 
found that Bmax values for [3H]nisoxetine binding increased with age from P21 to P90 
(CA1 and CA3) or remain unchanged (CA2 and dentate gyrus) (Figure 4.A-D).  In the 
locus coeruleus of rats, [3H]nisoxetine binding densities were found to peak at P10 then 
decrease into adulthood (Sanders et al., 2005).  Our data in mice locus coeruleus are 
consistent with this finding (Figure 4.E).  
It is important to evaluate NET expression in SERT-deficient mice because non-
SERT transporters of 5-HT, such as NET, could upregulate to compensate for the loss 




of SERT (Daws et al., 1998; 2005; 2009; Baganz et al., 2008).  We found that Bmax for 
[3H]nisoxetine binding was similar among SERT genotypes (Figure 4), which is 
consistent with previous findings showing that  NET expression remains unchanged in 
the CA3 region of hippocampus (Montañez et al., 2003).  NET protein levels appear to 
be uninfluenced by a constitutive reduction or loss of SERT expression.   
Increased NET expression in hippocampus as a function of increasing age 
correlated with a reduction in maximal antidepressant-like effect of DMI (Figure 5.A-D).  
This relationship was reversed in the locus coeruleus such that decreasing NET 
expression as a function of age correlated with a reduction in maximal antidepressant-
like effect for DMI (Figure 5.E).  The antidepressant action of TCAs is hypothesized to 
occur by increasing extracellular levels of NE, primarily via NET blockade in 
noradrenergic terminal regions, such as the hippocampus (Przegaliński et al., 1997; 
Herr et al., 2012).  Given that we found an inverse relationship between NET expression 
in hippocampus and antidepressant-response (increasing and decreasing, respectively) 
as a function of age, our data suggest brain regions other than hippocampus, such as 
the locus coeruleus, are likely prominent contributors to the antidepressant-like effects 
of DMI in the TST and warrant study.   
This study evaluated the dose-dependency of the antidepressant-like effects of 
DMI and provided a survey of [3H]nisoxetine binding to brain NET in juvenile, 
adolescent and adult SERT wild-type and SERT-deficient mice.  Regardless of SERT 
genotype, DMI potency and Emax were generally greater in juvenile mice than in adults.  
Of note, P28 SERT+/- and -/- were relatively insensitive to the antidepressant-like 
effects of DMI, suggesting that NET blocking antidepressants may be especially 




ineffective in adolescents harboring low expressing/function variants of SERT, whereas 
the opposite may be true for juveniles (of any SERT genotype).  Regardless of SERT 
genotype, NET binding increased with age in several noradrenergic terminal regions 
and decreased with age in the locus coeruleus.  These findings help lay the ground-
work for future studies investigating the age- and SERT genotype-dependency of NET 
acting drugs, such as reboxetine.  Studies to examine the mechanism by which age-
dependent variation in NET expression contribute to antidepressant response of NET 
blockers remains an important avenue for future inquiries.  The ultimate goal is to 
develop effective antidepressants for patients whose symptoms of depression are 
resistant to treatment with SSRIs. 
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Figure 1.  Influence of age and SERT genotype on the antidepressant-like effect of 
DMI.  (A) Dose-dependent reductions in immobility time in the TST in P21, P28 and P90 
SERT+/+ mice (B) SERT+/- mice and (C) SERT-/- mice.  (D)  Data from figure 1.A 
expressed as a percent of vehicle control.  (E)  Data from figure 1.B expressed as a 
percent of vehicle control.  (F)  Data from figure 1.C expressed as a percent of vehicle 
control.  Data obtained in males and females are pooled, because a multifactor ANOVA 
(sex, genotype, DMI) showed no main effect or interaction of sex with other factors (P > 
0.05) with one exception between sex and genotype (P < 0.01); however, multiple 
comparisons failed to show significant sex differences for each genotype (P > 0.05).  
Data are mean ± SEM.  Filled symbols represent data points that are significantly 
different from SERT genotype- and age-matched vehicle control as determined by 
Dunnett’s post hoc multiple comparisons test following a two-factor ANOVA.  * P < 0.05, 
* * P < 0.01 significant difference from SERT genotype matched P90 and # P < 0.05, # # 
P < 0.01 significant difference from SERT genotype matched P28 with Tukey’s post hoc 
multiple comparisons test after a two-factor ANOVA.  SERT+/+ n = 21-31 (males n = 9-
14 and females n = 10-20, pooled); SERT+/- n = 16-20 (males n = 8-10 and females n = 
8-12, pooled); SERT-/- n = 18-23 (males n = 8-10 and females n = 9-14, pooled), per 
data point. 
Figure 2.  Specific [3H]nisoxetine binding to NET in hippocampal regions as a 
function of age and SERT genotype.  Brain sections from P21, P28 and P90 SERT 
deficient mice incubated with the NET-specific ligand [3H]nisoxetine.  Non-specific 
binding was defined by mazindol (2.5 mM). (A) Representative coronal sections at the 




level of plate 47 (Paxinos and Franklin, 1997) in SERT+/+, SERT+/- and SERT-/- mice 
age P21, P28 or P90.  Boxed area in (A) is enlarged in (B), which shows representative 
thionine stained brain sections labeled with hippocampal regions quantified, which 
include the CA1, CA2, CA3 and dentate gyrus (DG).  (C) Example of saturation binding 
isotherms used to calculate Bmax and Kd values.  Curves include specific [
3H]nisoxetine 
binding values for the CA3 of P21, P28 and P90 SERT+/+ mice.  There was no main 
effect of sex on Bmax or Kd values, so male and female data are pooled (P > 0.05).  
Bmax values are summarized in Figure 4.  There were no significant differences in Kd 
among ages or between SERT+/+ and SERT+/- mice.  For SERT+/+ n = 5-9 (males n = 
4 and females n = 3-5, pooled), SERT+/- n = 6-10 (males n = 3-5 and females n = 2-4, 
pooled) and SERT-/- n = 4-7 (males n = 2-4 and females n = 2-4, pooled), mice per 
group.  See Table 2 and Figure 4 for summary of data.   
Figure 3.  Specific [3H]nisoxetine binding to NET in locus coeruleus as a function 
of age and SERT genotype.  Brain sections from P21, P28 and P90 mice were 
incubated with increasing concentrations of [3H]nisoxetine.  Non-specific binding was 
defined by mazindol (2.5µM).  (A) Representative coronal sections at the level of plate 
76 (Paxinos and Franklin, 1997) in SERT+/+, SERT+/- and SERT-/- mice age P21, P28 
or P90. Boxed area in (A) is enlarged in (B), which shows a representative thionine 
stained brain sections including locus coeruleus (LC).  (C) Example of saturation 
binding isotherms used to calculate Bmax and Kd values.  Curves include specific 
[3H]nisoxetine binding values for the LC of P21, P28 and P90 SERT+/+ mice.   Bmax 
values for this region are summarized in Figure 4.  There was no main effect of sex on 
Bmax or Kd values, so male and female data are pooled (P > 0.05).  For SERT+/+ n = 




5-9 (males n = 4 and females n = 3-5, pooled), SERT+/- n = 6-10 (males n = 3-5 and 
females n = 2-4, pooled) and SERT-/- n = 4-7 (males n = 2-4 and females n = 2-4, 
pooled), mice per group.  See Table 2 and Figure 4 for summary of data.   
Figure 4.  Bmax for [3H]nisoxetine binding to SERT in SERT+/+ and SERT+/- mice 
aged P21, P28 and P90.  Bmax values from P21, P28 and P90 SERT+/+, SERT+/- and 
SERT-/- mice in the CA1 (A), CA2 (B), CA3 (C), dentate gyrus (D) and locus coeruleus 
(E) were determined from 1-site curve fits as described in methods section.  Data are 
mean ± SEM.  * P < 0.05 represent significant difference from SERT genotype-matched 
P90, Dunnett’s post hoc multiple comparisons test after a two-factor ANOVA (age, 
SERT genotype).  Data are mean ± SEM pooled from male and female mice.  For 
SERT+/+ n = 5-9 (males n = 4 and females n = 3-5, pooled), SERT+/- n = 6-10 (males n 
= 3-5 and females, n = 2-4 pooled) and SERT-/- n = 4-7 (males n = 2-4 and females n = 
2-4, pooled), mice per group.   
Figure 5. Relationship between Emax values for DMI to produce antidepressant-
like effects in the TST and Bmax values for specific [3H]nisoxtine binding in locus 
coeruleus as a function of age and SERT genotype  The CA1 (A), CA2 (B), CA3 (C), 
dentate gyrus (D) and locus coeruleus (E) are shown.  Relationship between Emax and 
Bmax did not vary by SERT genotype, thus one line was used to fit data regardless of 
genotype.  Data taken from Figure 1.D-F (SERT+/+: n = 21-31, SERT+/-: n = 16-20, 
SERT-/-: n = 18-23, per data point) and Figure 4.A-E (SERT+/+: n = 5-9, SERT+/-: n = 
6-10, SERT-/-: n = 4-7, per age group).  Data are mean ± SEM, male and female data 
are pooled. 
 






















Table 1. Effect of age and SERT genotype on 
the potency (ED50) and maximal effect 














+/+ 7.5 *, # 70.1 ± 5.4 * 
+/- 17.4 # 68.5 ± 7.0 
-/- 17.1 # 62.4 ± 8.9 # 
P28 +/+ 23.7 * 57.5 ± 10.6 
+/- 36.3 41.3 ± 8.6 
-/- 45.2 † 32.3 ± 9.2 
P90 +/+ 37.3 47.0 ± 6.1 
 +/- 29.1 47.3 ± 7.7 
-/- 30.5 51.9 ± 9.2 




Table 1. Influence of age and SERT genotype on the potency (ED50) and maximal 
effect (Emax) of DMI to reduce immobility time in the TST.  Data are mean ± SEM; 
values calculated from data shown in figures 1.D, E and F; * P < 0.05 difference from 
SERT genotype matched P90; # P < 0.05 difference from SERT genotype matched P28; 
† P < 0.05 difference from age matched SERT+/+ group; for ED50 comparisons made by 
F ratio test to compare intercepts; for Emax comparisons made by Tukey’s post hoc 
multiple comparisons test after a two-factor ANOVA; because there were no statistically 
significant sex differences, data for male and female mice were pooled; SERT+/+ n = 
21-31 (males n = 9-14 and females n = 10-20, pooled); SERT+/- n = 16-20 (males n = 
8-10 and females n = 8-12, pooled); SERT-/- n = 18-23 (males n = 8-10 and females n = 
















Table 2. Summary of Bmax values for specific 
[3H]nisoxetine binding in SERT+/+, SERT+/- and 
SERT-/- mice. 
Genotype P21 P28 P90 
Prefrontal Cortex 
SERT+/+ 228 ± 23* 275 ± 26 314 ± 36 
SERT+/- 229 ± 23 251 ± 21 290 ± 30 
SERT-/- 206 ± 19 271 ± 35 225 ± 26 
Amygdala 
SERT+/+ 193 ± 27 137 ± 14* 233 ± 29 
SERT+/- 150 ± 29 165 ± 14 191 ± 24 
SERT-/- 157 ± 24 146 ± 20 155 ± 21 
Dorsal Raphe 
SERT+/+ 619 ± 40 551 ± 35 539 ± 35 
SERT+/- 560 ± 57 562 ± 31 578 ± 27 
SERT-/- 565 ± 20 543 ± 24 536 ± 36 




Table 2. Summary of Bmax values for specific [3H]nisoxetine binding in SERT+/+, 
SERT+/- and SERT-/- mice. Data are mean ± SEM fmol/mg pr.  * P < 0.05 different 
from SERT genotype matched P90 group; Dunnett’s multiple comparisons test after 
two-factor ANOVA. For SERT+/+ n = 5-9 (males n = 4 and females n = 3-5, pooled), 
SERT+/- n = 6-10 (males n = 3-5 and females n = 2-4, pooled) and SERT-/- n = 4-7 
(males n = 2-4 and females n = 2-4, pooled), mice per group.   
 
  





